IRIS
GALETTI, Maricla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.122
AS - Asia 4.356
EU - Europa 3.741
SA - Sud America 589
AF - Africa 242
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.060
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.017
SG - Singapore 1.447
CN - Cina 1.225
IT - Italia 1.061
VN - Vietnam 831
FI - Finlandia 548
IE - Irlanda 482
BR - Brasile 446
SE - Svezia 434
DE - Germania 331
HK - Hong Kong 301
FR - Francia 182
UA - Ucraina 141
ZA - Sudafrica 135
NL - Olanda 123
GB - Regno Unito 114
IN - India 112
TR - Turchia 102
RU - Federazione Russa 90
CA - Canada 62
AR - Argentina 60
AT - Austria 51
CI - Costa d'Avorio 49
BD - Bangladesh 40
BE - Belgio 40
KR - Corea 40
PL - Polonia 36
ES - Italia 29
MX - Messico 28
ID - Indonesia 27
IQ - Iraq 27
JP - Giappone 27
CO - Colombia 21
PK - Pakistan 21
EC - Ecuador 20
PH - Filippine 19
TH - Thailandia 17
SA - Arabia Saudita 15
MA - Marocco 14
CZ - Repubblica Ceca 13
UZ - Uzbekistan 13
VE - Venezuela 13
LT - Lituania 11
EG - Egitto 9
PY - Paraguay 9
TN - Tunisia 9
AL - Albania 8
KE - Kenya 8
MY - Malesia 8
CH - Svizzera 7
HU - Ungheria 7
IR - Iran 7
JO - Giordania 7
SY - Repubblica araba siriana 7
AZ - Azerbaigian 6
BO - Bolivia 6
CL - Cile 6
KZ - Kazakistan 6
NP - Nepal 6
TW - Taiwan 6
AU - Australia 5
KG - Kirghizistan 5
LB - Libano 5
PE - Perù 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
PT - Portogallo 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
GE - Georgia 3
GR - Grecia 3
LU - Lussemburgo 3
LV - Lettonia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
GA - Gabon 2
HR - Croazia 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TJ - Tagikistan 2
AD - Andorra 1
BB - Barbados 1
BF - Burkina Faso 1
BW - Botswana 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
EU - Europa 1
Totale 14.045
Salva come PNG Salva come JPEG
Città #
Singapore 763
Ashburn 602
Dallas 585
Dublin 481
Chandler 458
San Jose 405
Parma 381
Santa Clara 314
Hong Kong 281
Beijing 277
Ann Arbor 273
Ho Chi Minh City 258
Hanoi 175
Jacksonville 158
Dearborn 153
Boardman 148
Johannesburg 128
Los Angeles 124
Shanghai 113
New York 110
Munich 104
Nanjing 97
Hefei 95
Chicago 86
Lauterbourg 81
Princeton 74
Izmir 72
Milan 70
Bremen 56
São Paulo 54
San Mateo 51
Abidjan 49
Helsinki 47
Wilmington 47
Council Bluffs 46
Vienna 44
Moscow 42
Haiphong 40
Bologna 39
Shenyang 39
Nanchang 36
Da Nang 35
Buffalo 34
Columbus 31
Kunming 30
Modena 30
Des Moines 29
Rome 29
The Dalles 29
Tianjin 29
Warsaw 29
Marseille 28
Toronto 28
Jinan 27
Frankfurt am Main 26
Seattle 25
Seoul 25
London 24
Brussels 23
Stockholm 23
Turku 23
Jakarta 22
Denver 21
Hebei 21
Reggio Emilia 21
Tokyo 21
Guangzhou 20
Houston 20
Phoenix 20
Nuremberg 18
Atlanta 17
Chennai 16
Boston 15
Brasília 15
Brooklyn 15
Montreal 15
Poplar 15
Redmond 15
Amsterdam 14
Changsha 14
Jiaxing 14
Manchester 14
Rio de Janeiro 14
Norwalk 13
Orem 13
Pune 13
Tashkent 13
Verona 13
Zhengzhou 13
Bến Tre 12
Düsseldorf 12
Leawood 12
Wayne 12
Woodbridge 12
Can Tho 11
Bari 10
Brescia 10
Dong Ket 10
Florence 10
New Delhi 10
Totale 8.589
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 273
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Highly-defined bioprinting of long-term vascularized scaffolds with Bio-Trap: Complex geometry functionalization and process parameters with computer aided tissue engineering 248
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 242
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation 206
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 202
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(II) complexes on p53 and p53-null tumour cell lines 191
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 191
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 188
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 181
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 180
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 179
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 176
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 175
Nanoparticles exposure: In-vitro and in-vivo investigation to evaluate cardiovascu1ar risk factors in normal and failing cardiac tissue [Esposizione a nanoparticelle: Studi in-vitro ed in-vivo per valutare i fattori di rischio cardiovascolari in cuori normali e patologici] 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 169
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 166
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 160
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 159
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 158
Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles 157
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 156
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 155
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Cardiac kinematic parameters computed from video of in situ beating heart 155
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
SiO2/SiC core-shell nanowires for nanomedicine applications 147
New MDR1 inhibitors for overcoming multidrug resistance 146
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 144
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
SiO2/SiC core-shell nanowires for nanomedicine applications 141
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 140
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 139
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 139
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 138
Study and characterization of a new magnetic nanocomposite system for nanomedicine 135
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 131
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 126
Interaction between occupational radon exposure and tobacco smoke: a systematic review 124
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 124
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 120
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 119
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 117
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 114
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 113
Chapter 9 - Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes 113
Synergistic activity of letrozole and sorafenib on breast cancer cells 105
In vitro characterization of efflux and metabolism of gefitinib 105
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 104
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 104
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 103
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 99
The inducible coexpression of p53 and FHIT has a synergistic anti-proliferative effect in calu-1 lung cancer cell line 95
Optimizing EGFR inhibitor treatment in non small cell lung cancer 95
Espressione inducibile di Fhit e p53 in cellule di carcinoma polmonare non a piccole cellule 91
Effect of inducile FHIT and p53 expression in Calu-1 lung cancer cell line. 90
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 89
New irreversible inhibitors of EGFR tyrosine kinase activity to circumvent iressa resistance 89
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 88
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 75
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 33
null 31
Totale 14.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.933
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021165 0 0 0 0 0 0 0 0 0 23 101 41
2021/2022427 30 19 22 29 15 9 56 36 23 24 24 140
2022/20231.835 151 220 119 107 171 204 18 137 586 17 78 27
2023/2024969 44 75 48 37 67 174 77 87 39 59 105 157
2024/20252.729 128 126 161 205 248 304 182 131 347 220 241 436
2025/20265.527 477 486 846 609 777 322 662 166 789 393 0 0
Totale 14.257